Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 3Withdrawn 2Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 181pembrolizumab 156Pemetrexed 129Cisplatin 97Drug Therapy 67Paclitaxel 59osimertinib 56Magnetic Resonance Spectroscopy 50durvalumab 49Specimen Handling 49Radiotherapy 49Nivolumab 49atezolizumab 43Docetaxel 43Etoposide 40Bevacizumab 39Blood Specimen Collection 33tislelizumab 31Radiosurgery 31Gemcitabine 29130-nm albumin-bound paclitaxel 27Immunotherapy 25Immune Checkpoint Inhibitors 25cemiplimab 23Injections 23aflutinib 20Cetuximab 18Biopsy 18Standard of Care 17Platinum Compounds 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Thymalfasin × Thoracic × Clear all
NCT06598839 2024-09-19

Immuno-effect of Tα1 for Stage I NSCLC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase NA Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡